Biovail Settles Canadian Cardizem Suit

Law360, New York (April 23, 2008, 12:00 AM EDT) -- Pharmaceutical company Biovail Corp. has put another shareholder class action behind it, agreeing to settle with a Canadian pension fund that claimed the company made misleading statements in promoting its hypertension drug Cardizem LA.

Biovail said Wednesday that it had entered into a settlement agreement with the Canadian Commercial Workers Industry Pension Plan under which the fund will be entitled to part of the $138 million settlement reached in a parallel class action last year. Neither the Toronto-based company nor any of the individual defendants named...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.